ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Joe Burnett – Chief Executive Officer Danilo D’Alessandro – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets William Wood – B. Riley Securities Operator Greetings, and welcome to the ClearPoint Neuro, Inc. First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer ses ...

WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdag: CLPT . . © 2024 CLEARPOINT NEURO This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company's expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future market of its products and services, and other performance and results. These forward looking statements are based on management's ...

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 FORM 10-Q Or Commission file number: 001-34822 Delaware 58-2394628 (State or Other Jurisdiction (IRS Employer of Incorporation or Organization) Identification Number) (888) 287-9109 (Registrant's Telephone Number, Including Area Code) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value per share CLPT Nasdaq Capital M ...

SOLANA BEACH, CA, May 7, 2024 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024. | --- | --- | |-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

koto_feja ClearPoint Neuro’s (NASDAQ:CLPT) fourth quarter results were strong, and the first quarter of 2024 is also shaping up well. Despite this, the stock is down significantly over the past 2 months on the back of a sizeable equity raise and interest rate fears. The last time I wrote about ClearPoint I suggested it was a buy, as the company was reasonably valued and approaching an inflection point. This still appears to be the case, with recent developments reducing uncertainty regarding the company ...

SOLANA BEACH, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner PTC Therapeutics on completion of its BLA submission to the U.S. Food and Drug Administration (FDA) for the approval of Upstaza™ (eladocagene exuparvovec), an investigational treatment for AADC Deficiency. If approved, Upstaza™ would become the first therapy t ...

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2023 Earnings Conference Call March 12, 2024 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Emily Christy - Stifel William Wood - B. Riley Securities Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. Comments made ...

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.64%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produced a loss of $0.20, delivering a surprise of 20%.Over the last four quarters, the company has surp ...

ClearPoint Neuro, Inc. (CLPT) recently announced the publication of preclinical results of an in vivo validation study in the Journal of Neurosurgery. The aim of the research, which was conducted by the company and its Swedish partner, Clinical Laserthermia Systems AB, was to assess the safety, accuracy and efficacy of the Prism System.The data demonstrated that the ClearPoint Prism Neuro Laser Therapy System provides accurate and near real-time temperature of the brain tissue. Additionally, the morphology ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value per share CLPT Nasdaq Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-K ___________________________ þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA ...